Salud financiera de hoja de balance de Core Scientific

Salud financiera controles de criterios 2/6

Core Scientific tiene un patrimonio de los accionistas total de $-418.7M y una deuda total de $850.3M, lo que sitúa su ratio deuda-patrimonio en -203.1%. Sus activos y pasivos totales son $705.5M y $1.1B respectivamente.

Información clave

-203.1%

Ratio deuda-patrimonio

US$850.32m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$42.15m
Patrimonio	-US$418.73m
Total pasivo	US$1.12b
Activos totales	US$705.46m

Actualizaciones recientes sobre salud financiera

Recent updates

Core Scientific: A Solid Bitcoin Mining Play

Oct 11

Core Scientific: A Buy On Leading Bitcoin Production Numbers

Aug 11

Core Scientific July bitcoin production rose 10.4% M/M with new deployments and multiple facilities

Aug 05

Core Scientific signs $100M in committed equity facility for enhancing liquidity

Jul 21

Análisis de la situación financiera

Pasivos a corto plazo: CORZ.Q tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: CORZ.Q tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: CORZ.Q tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: CORZ.Q tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable CORZ.Q tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: CORZ.Q no es rentable, pero tiene suficiente cash runway para más de 3 años, incluso con un flujo de caja libre positivo que se reduce un 11.1% al año.

Salud financiera de hoja de balance de Core Scientific

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Core Scientific, Inc. Emerged from Bankruptcy

Core Scientific, Inc. Com Deleted from OTC Equity

Modified Fourth Amended Joint Reorganization Plan and Disclosure Statement Approved for Core Scientific, Inc.

Amended Reorganization Plan Filed by Core Scientific, Inc.

Core Scientific, Inc. announced delayed 10-Q filing

Core Scientific's Common Stock to Be Delisted from Nasdaq

Recent updates

Core Scientific, Inc. to Report Q1, 2024 Results on May 08, 2024

Core Scientific, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

Core Scientific, Inc. Emerged from Bankruptcy

Core Scientific, Inc. Com Deleted from OTC Equity

Modified Fourth Amended Joint Reorganization Plan and Disclosure Statement Approved for Core Scientific, Inc.

Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million.

Amended Reorganization Plan Filed by Core Scientific, Inc.

Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million.

Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million.

Core Scientific, Inc. announced that it expects to receive $53.9 million in funding from Bitmain Technologies Limited

Core Scientific, Inc. Appoints Adam Sullivan as Chief Executive Officer

Core Scientific, Inc. Appoints Adam Sullivan as President

Core Scientific, Inc. announced delayed 10-Q filing

Core Scientific, Inc.(OTCPK:CORZ.Q) dropped from NASDAQ Composite Index

Core Scientific's Common Stock to Be Delisted from Nasdaq

Core Scientific, Inc. Filed for Bankruptcy

Core Scientific Receives A Written Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price Requirement

Stacie Olivares Resigns as A Director of Core Scientific, Inc

Core Scientific, Inc. Appoints Todd Duchene as President and Chief Legal Officer, Effective November 14, 2022

Core Scientific, Inc. announced delayed 10-Q filing

Core Scientific, Inc Contemplates Bankruptcy

Core Scientific, Inc. Announces Management Changes

Core Scientific: A Solid Bitcoin Mining Play

Core Scientific, Inc. announced delayed 10-Q filing

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Core Scientific, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2022

Core Scientific: A Buy On Leading Bitcoin Production Numbers

Core Scientific July bitcoin production rose 10.4% M/M with new deployments and multiple facilities

Core Scientific, Inc. announced that it expects to receive $100 million in funding from B. Riley Principal Capital II, LLC

Core Scientific signs $100M in committed equity facility for enhancing liquidity

Price target decreased to US$8.02

Core Scientific, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus EPS estimates fall by 13%

Why I'm Very Optimistic On Core Scientific's Future

Price target decreased to US$11.00

Co-Founder recently sold US$9.0m worth of stock

Consensus forecasts updated

Core Scientific, Inc. Provides Operating Guidance for the Year 2022

Price target decreased to US$16.19

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Robust Earnings May Not Tell The Whole Story For Core Scientific (NASDAQ:CORZ)

Core Scientific, Inc. announced that it expects to receive $75 million in funding from B. Riley Commercial Capital, LLC

Core Scientific Posts 3849% EBITDA Growth And Bitcoin Holdings Worth ~$400M

Core Scientific, Inc. Announces CFO Changes

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera